DocWire News Editors

DocwireNews

A study presented at the 2020 ASH Annual Meeting found that R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with tafasitamab with or without lenalidomide is a safe treatment option for patients with treatment-na&iuml;ve diffuse large B-cell lymphoma (DLBCL).Tafasitamab is a humanized, Fc-enhanced, anti-CD19 monoclonal antibody with improved antibody-dependent cellular cytotoxicity and phagocytosis. Tafasitamab monotherapy has shown clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma. In the phase II, single-arm L-MIND study, tafasitamab plus lenalidomide induced a complete response in a high proportion of patients with relapsed/refractory DLBCL.The randomized, phase Ib First-MIND study is assessing R-CHOP plus tafasitamab or R-CHOP plus tafasitamab and lenalidomide in patients with newly diagnosed DLBCL.Adult treatment-na&iuml;ve patients with histologically confirmed DLBCL not otherwise specified with intermediate- to high-risk disease and an Eastern Cooperative Oncology Group performance status score of 0-2 were included in the study. Patients with known double- or triple-hit lymphoma and transformed lymphoma were excluded.Patients (n=36) were treated with six 21-day cycles of tafasitamab 12 mg/kg intravenously (IV) plus R-CHOP (arm A; n=18; median age at baseline, 67 years; range, 47-76 years) or tafasitamab 12 mg/kg IV plus lenalidomide 25 mg orally in addition to R-CHOP (arm B; n=18; median age at baseline, 65 years; range, 40-74 years). All patients received granulocyte-colony stimulating factor prophylaxis. Most patients had advanced disease (stages III/IV; 92%), and approximately 50% had bulky disease.The data presented at the ASH Annual Meeting were from the safety run-in phase consisting of 24 patients: 13 in arm A and 11 in arm B. All patients completed the first treatment cycle&mdash;88% of patients entered into cycle 2, and 50% entered into cycle 3.Cell of origin was determined to be germinal center B-cell (GCB) DLBCL in 13%, non-GCB DLBCL in 42%, and not yet classified in 46% of cases. A total of 248 treatment-related adverse events (AEs) occurred: 111 in arm A and 137 in arm B. Grade &ge;3 neutropenia occurred in 54% of patients in arm A and 46% in arm B. Grade &ge;3 thrombocytopenia occurred in 8% and 18%, respectively. Diarrhea, fatigue, and vomiting were comparable between the two arms, and febrile neutropenia occurred in one patient in each cohort.A total of 23 serious AEs were reported: 11 in arm A and 12 in arm B. One suspected unexpected serious AE was reported in arm B: pneumocystis jirovecii pneumonia. No treatment-related deaths occurred.&ldquo;R-CHOP can be safely combined with tafasitamab or tafasitamab plus lenalidomide in patients with treatment-na&iuml;ve DLBCL. Toxicities appear to be similar to what is expected with R-CHOP alone or in combination with lenalidomide,&rdquo; the researchers concluded. The study is ongoing.ReferenceBelada D, Nowakowski GS, Bergua Burgues JM, et al. A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. Abstract 3028. Presented at the 62nd American Society of Hematology Annual Meeting &amp; Exposition, December 2-11, 2020.

Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

Addition of Tafasitamab to R-CHOP Is Safe for DLBCL

ASH Annual Meeting 2020

A study presented at the 2020 ASH Annual Meeting found that R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with tafasitamab with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe